Therapeutic antibodies: successes, limitations and hopes for the future
Open accessAbstract
With more than 20 molecules in clinical use, monoclonal antibodies have finally come of age as therapeutics, generating a market value of $11 billion in 2004, expected to reach $26 billion by 2010. While delivering interesting results in the treatment of several major diseases including autoimmune, cardiovascular and infectious diseases, cancer and inflammation, clinical trials and research are generating a wealth of useful information, for instance about associations of clinical responses with Fc receptor polymorphisms and the infiltration and recruitment of effector cells into targeted tissues. Some functional limitations of therapeutic antibodies have come to light such as inadequate pharmacokinetics and tissue accessibility as well as impaired interactions with the immune system, and these deficiencies point to areas where additional research is needed. This review aims at giving an overview of the current state of the art and describes the most promising avenues that are being followed to create the next generation of antibody‐based therapeutic agents. This article is part of a themed section on Vector Design and Drug Delivery. For a list of all articles in this section see the end of this paper, or visit: http://www3.interscience.wiley.com/journal/121548564/issueyear?year=2009
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Both serum- and mAb-based therapeutics are costly to produce, store, and deliver as they require a cold supply chain and are often administered intravenously.
“both serum‐ and mAb‐based therapeutics are costly to produce, store, and deliver as they require a cold supply chain and are often administered intravenously (Chames et al, 2009; Keizer et al, 2010).”
From mRNA mediates passive vaccination against infectious agents, toxins, and tumors (2017) · cites this paper as Chames et al, 2009
The Current limitations section (page unavailable) says therapeutic mAbs have extremely high production costs and are injected in large amounts. It does not establish that serum-based therapeutics share those costs, or that either type requires a cold supply chain, is costly to store and deliver, or is often administered intravenously. (LLM, conf=0.88)
Experimental — accuracy not yet measuredMonoclonal antibody modes of action have major limitations, including redundancy of molecular pathways leading to cancer cell survival, effects of the microenvironment, suboptimal interaction with effector cells due to alternative Fc glycosylation or Fc receptor polymorphism, activation of inhibitory receptors, and competition with circulating IgG.
“limitations in their modes of action, including redundancy of molecular pathways leading to cancer cell survival, effects of the microenvironment, suboptimal interaction with effector cells due to alternative Fc glycosylation or Fc receptor polymorphism, activation of inhibitory receptors, and competition with circulating IgG. 2”
From Bispecific antibodies for cancer therapy: The light at the end of the tunnel? (2009) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
Köhler, G., & Milstein, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,200 · see citing works
Smith, G. P. (1985) · Science · doi:10.1126/science.4001944 · Cited by 4,143 · see citing works
Naturally occurring antibodies devoid of light chains
Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hammers, C., Songa, E. B., Bendahman, N., & Hammers, R. (1993) · Nature · doi:10.1038/363446a0 · Cited by 3,241 · see citing works
Phage antibodies: filamentous phage displaying antibody variable domains
McCafferty, J., Griffiths, A. D., Winter, G. P., & Chiswell, D. J. (1990) · Nature · doi:10.1038/348552a0 · Cited by 2,427 · see citing works
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346 · see citing works
Engineered antibody fragments and the rise of single domains
Holliger, P., & Hudson, P. J. (2005) · Nature Biotechnology · doi:10.1038/nbt1142 · Cited by 1,928 · see citing works
Cartron, G., Dacheux, L., Salles, G., Solal‐Céligny, P., BARDOS, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,902 · see citing works
Single-Chain Antigen-Binding Proteins
Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S., Lee, T. T., Pope, S. H., Riordan, G. S., & Whitlow, M. D. (1988) · Science · doi:10.1126/science.3140379 · Cited by 1,509 · see citing works
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413 · see citing works
Replacing the complementarity-determining regions in a human antibody with those from a mouse
Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S., & Winter, G. (1986) · Nature · doi:10.1038/321522a0 · Cited by 1,406 · see citing works
Weng, W., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300 · see citing works
Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J. B., Xie, D., Lai, J., Stadlen, A., Li, B., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009483200 · Cited by 1,164 · see citing works
Ward, E. S., Güssow, D., Griffiths, A. D., Jones, P., & Winter, G. P. (1989) · Nature · doi:10.1038/341544a0 · Cited by 1,003 · see citing works
Winter, G., & Milstein, C. (1991) · Nature · doi:10.1038/349293a0 · Cited by 946 · see citing works
"Diabodies": small bivalent and bispecific antibody fragments.
Holliger, P., Prospero, T. D., & Winter, G. P. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.14.6444 · Cited by 879 · see citing works
Engineered antibody Fc variants with enhanced effector function
Lazar, G. A., Dang, W., Karki, S., Vafa, O., Peng, J. S., Hyun, L., Chan, C. S. C., Chung, H. S., Eivazi, A., Yoder, S. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508123103 · Cited by 805 · see citing works
Monoclonal antibody successes in the clinic
Reichert, J. M., Rosensweig, C., Faden, L. B., & Dewitz, M. C. (2005) · Nature Biotechnology · doi:10.1038/nbt0905-1073 · Cited by 736 · see citing works
Targeting and tracing antigens in live cells with fluorescent nanobodies
Rothbauer, U., Zolghadr, K., Tillib, S. V., Nowak, D., Schermelleh, L., Gahl, A., Backmann, N., Conrath, K., Muyldermans, S., Cardoso, M. C., et al. (2006) · Nature Methods · doi:10.1038/nmeth953 · Cited by 715 · see citing works
Adams, G. P., Schier, R., McCall, A. M., Simmons, H. H., Horak, E. M., Alpaugh, R. K., Marks, J. D., & Weiner, L. M. (2001) · PubMed · Cited by 623 · see citing works
Yamane‐Ohnuki, N., Kinoshita, S., Inoue‐Urakubo, M., Kusunoki, M., Iida, S., Nakano, R., Wakitani, M., Niwa, R., Sakurada, M., Uchida, K., et al. (2004) · Biotechnology and Bioengineering · doi:10.1002/bit.20151 · Cited by 572 · see citing works
Optimization of humanized IgGs in glycoengineered Pichia pastoris
Li, H., Sethuraman, N., Stadheim, T. A., Zha, D., Prinz, B., Ballew, N. L., Bobrowicz, P., Choi, B., Cook, W. J., Cukan, M. C., et al. (2006) · Nature Biotechnology · doi:10.1038/nbt1178 · Cited by 428 · see citing works
Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor
Cox, K. M., Sterling, J. D., Regan, J. T., Gasdaska, J. R., Frantz, K., Peele, C. G., Black, A., Passmore, D., Moldovan-Loomis, C., Srinivasan, M., et al. (2006) · Nature Biotechnology · doi:10.1038/nbt1260 · Cited by 421 · see citing works
Giritch, A., Marillonnet, S., Engler, C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606631103 · Cited by 419 · see citing works
Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels
Vaccaro, C., Zhou, J., Ober, R. J., & Ward, E. S. (2005) · Nature Biotechnology · doi:10.1038/nbt1143 · Cited by 407 · see citing works
Immunotoxin Treatment of Cancer
Pastan, I. H., Hassan, R., FitzGerald, D. J., et al. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.58.070605.115320 · Cited by 359 · see citing works
A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier.
Fujimori, K., Covell, D. G., Fletcher, J. E., & Weinstein, J. N. (1990) · PubMed · Cited by 359 · see citing works
Dhodapkar, K. M., Krasovsky, J., Williamson, B., & Dhodapkar, M. V. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011097 · Cited by 348 · see citing works
A hapten-specific chimaeric IgE antibody with human physiological effector function
Neuberger, M. S., Williams, G. T., Mitchell, E. B., Jouhal, S., Flanagan, J. G., & Rabbitts, T. H. (1985) · Nature · doi:10.1038/314268a0 · Cited by 289 · see citing works
Antibody constructs in cancer therapy
Beckman, R. A., Weiner, L. M., & Davis, H. M. (2006) · Cancer · doi:10.1002/cncr.22402 · Cited by 280 · see citing works
BiTEs: bispecific antibody constructs with unique anti-tumor activity
Wolf, E., Hofmeister, R., Kufer, P., Schlereth, B., & Baeuerle, P. A. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03554-3 · Cited by 260 · see citing works
Antibodies, Fc receptors and cancer
Nimmerjahn, F., & Ravetch, J. V. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.01.005 · Cited by 235 · see citing works
Müller, D., Karle, A. C., Meißburger, B., Höfig, I., Stork, R., & Kontermann, R. E. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700820200 · Cited by 222 · see citing works
Lindhofer, H., Mocikat, R., Steipe, B., & Thierfelder, S. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.1.219 · Cited by 213 · see citing works
Natural and designer binding sites made by phage display technology
Hoogenboom, H. R., & Chames, P. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01667-4 · Cited by 213 · see citing works
Self-citationManufacturing of recombinant therapeutic proteins in microbial systems
Graumann, K., & Premstaller, A. (2006) · Biotechnology Journal · doi:10.1002/biot.200500051 · Cited by 208 · see citing works
Zeidler, R., Reisbach, G., Wollenberg, B., Lang, S., Chaubal, S., Schmitt, B., & Lindhofer, H. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.3.1246 · Cited by 204 · see citing works
Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs
Holt, L. J., Basran, A., Jones, K. H., Chorlton, J., Jespers, L. S., Brewis, N., & Tomlinson, I. M. (2008) · Protein Engineering Design and Selection · doi:10.1093/protein/gzm067 · Cited by 193 · see citing works
Dooley, H. M. (2003) · Molecular Immunology · doi:10.1016/s0161-5890(03)00084-1 · Cited by 185 · see citing works
Colby, D. W., Chu, Y., Cassady, J. P., Duennwald, M. L., Zazulak, H., Webster, J. M., Messer, A. C., Lindquist, S. L., Ingram, V. M., & Wittrup, K. D. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408134101 · Cited by 183 · see citing works
Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody
Ruf, P., & Lindhofer, H. (2001) · Blood · doi:10.1182/blood.v98.8.2526 · Cited by 174 · see citing works
Tanaka, T. U., Williams, R. L., & Rabbitts, T. H. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601744 · Cited by 151 · see citing works
Nguyen, A., Reyes, A. E., Zhang, M., McDonald, P., Wong, W., Damico, L. A., & Dennis, M. S. (2006) · Protein Engineering Design and Selection · doi:10.1093/protein/gzl011 · Cited by 141 · see citing works
Visintin, M., Settanni, G., Maritan, A., Graziosi, S., Marks, J. D., & Cattaneo, A. (2002) · Journal of Molecular Biology · doi:10.1006/jmbi.2002.5392 · Cited by 135 · see citing works
Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective
Desjarlais, J. R., Lazar, G. A., Zhukovsky, E. A., & Chu, S. Y. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.08.009 · Cited by 134 · see citing works
Preithner, S., Elm, S., Lippold, S., Locher, M., Wolf, A., da Silva, A. J., Baeuerle, P. A., & Prang, N. S. (2005) · Molecular Immunology · doi:10.1016/j.molimm.2005.07.010 · Cited by 131 · see citing works
Kaspar, M., Trachsel, E., & Neri, D. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0283 · Cited by 125 · see citing works
Cheung, N. V., Sowers, R. S., Vickers, A. J., Cheung, I. Y., Kushner, B. H., & Gorlick, R. G. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.6011 · Cited by 120 · see citing works
Lynch, S. M., Zhou, C., & Messer, A. C. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.11.096 · Cited by 117 · see citing works
Intracellular Antibodies (Intrabodies) and Their Therapeutic Potential
Lo, A. S., Zhu, Q. K., & Marasco, W. A. (2007) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-73259-4_15 · Cited by 116 · see citing works
Engineered vascular‐targeting antibody‐interferon‐γ fusion protein for cancer therapy
Ebbinghaus, C., Ronca, R., Kaspar, M., Grabulovski, D., Berndt, A., Kosmehl, H., Zardi, L., & Neri, D. (2005) · International Journal of Cancer · doi:10.1002/ijc.20952 · Cited by 115 · see citing works
Tanaka, T. U., Lobato, M. N., & Rabbitts, T. H. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(03)00836-2 · Cited by 114 · see citing works
The T-Body Approach: Redirecting T Cells with Antibody Specificity
Eshhar, Z. (2007) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-73259-4_14 · Cited by 111 · see citing works
Stork, R., Müller, D., & Kontermann, R. E. (2007) · Protein Engineering Design and Selection · doi:10.1093/protein/gzm061 · Cited by 111 · see citing works
Luginbühl, B., Kanyo, Z. F., Jones, R. M., Fletterick, R. J., Prusiner, S. B., Cohen, F. E., Williamson, R. A., Burton, D. R., & Plückthun, A. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.07.027 · Cited by 106 · see citing works
β-site specific intrabodies to decrease and prevent generation of Alzheimer's Aβ peptide
Paganetti, P., Calanca, V., Galli, C., Stefani, M., & Molinari, M. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200410047 · Cited by 101 · see citing works
Béhar, G., Sibéril, S., Groulet, A., Chames, P., Pugnière, M., Boix, C., Sautès‐Fridman, C., Teillaud, J., & Baty, D. (2007) · Protein Engineering Design and Selection · doi:10.1093/protein/gzm064 · Cited by 99 · see citing works
Self-citationStork, R., Zettlitz, K. A., Müller, D., Rether, M., Hanisch, F., & Kontermann, R. E. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709179200 · Cited by 97 · see citing works
Gillies, S. D., Lan, Y., Williams, S., Carr, F., Forman, S. J., Raubitschek, A. A., & Lo, K.-M. (2005) · Blood · doi:10.1182/blood-2004-09-3533 · Cited by 93 · see citing works
Aires‐da‐Silva, F., Santa‐Marta, M., Freitas‐Vieira, A., et al. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.04.062 · Cited by 91 · see citing works
Amann, M., Brischwein, K., Lutterbuese, P., Parr, L., Petersen, L., Lorenczewski, G., Krinner, E., Bruckmeier, S., Lippold, S., Kischel, R., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2182 · Cited by 90 · see citing works
Human Monoclonal Antibodies from Transgenic Mice
Lönberg, N. (2007) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-73259-4_4 · Cited by 85 · see citing works
Adams, G. P., Shaller, C. C., Dadachova, E., Simmons, H. H., Horak, E. M., Tesfaye, A., Klein–Szanto, A. J., Marks, J. D., Brechbiel, M. W., & Weiner, L. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2382 · Cited by 84 · see citing works
Recombinant bispecific antibodies for cellular cancer immunotherapy.
Müller, D., & Kontermann, R. E. (2007) · PubMed · Cited by 83 · see citing works
Bispecific Antibodies: Molecules That Enable Novel Therapeutic Strategies
Fischer, N., & Léger, O. J. P. (2007) · Pathobiology · doi:10.1159/000101046 · Cited by 77 · see citing works
Armour, K. L., van de Winkel, J. G. J., Williamson, L. M., & Clark, M. (2003) · Molecular Immunology · doi:10.1016/j.molimm.2003.08.004 · Cited by 74 · see citing works
Nechansky, A., Schuster, M., Jost, W., Siegl, P., Wiederkum, S., Gorr, G., & Kircheis, R. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2006.08.013 · Cited by 68 · see citing works
A Fully Human Antitumor ImmunoRNase Selective for ErbB-2-Positive Carcinomas
Lorenzo, C. D., Arciello, A., Cozzolino, R., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3717 · Cited by 67 · see citing works
Courtête, J., Sibler, A., Zeder‐Lutz, G., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0808 · Cited by 61 · see citing works
Genetic engineering of T cell specificity for immunotherapy of cancer
Willemsen, R. A., Debets, R., Chames, P., & Bolhuis, R. L. H. (2002) · Human Immunology · doi:10.1016/s0198-8859(02)00730-9 · Cited by 59 · see citing works
Self-citationRobinson, M. K., Shaller, C. C., Garmestani, K., Plascjak, P. S., Hodge, K. M., Yuan, Q., Marks, J. D., Waldmann, T. A., Brechbiel, M. W., & Adams, G. P. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1250 · Cited by 59 · see citing works
Molecular aspects of human FcγR interactions with IgG: Functional and therapeutic consequences
Sibéril, S., Dutertre, C., Boix, C., Bonnin, E., Ménez, R., Stura, E. A., Jorieux, S., Fridman, W. H., & Teillaud, J. (2006) · Immunology Letters · doi:10.1016/j.imlet.2006.05.009 · Cited by 53 · see citing works
Blick, S. K. A., & Curran, M. P. (2007) · BioDrugs · doi:10.2165/00063030-200721030-00006 · Cited by 52 · see citing works
Paz, K., Brennan, L., Iacolina, M., Doody, J., Hadari, Y., & Zhu, Z. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0174 · Cited by 51 · see citing works
Böldicke, T. W. (2007) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2007.00002.x · Cited by 49 · see citing works
Visintin, M. (2004) · Methods · doi:10.1016/j.ymeth.2004.04.008 · Cited by 44 · see citing works
Antibody engineering and its applications in tumor targeting and intracellular immunization
Chames, P., & Baty, D. (2000) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2000.tb09197.x · Cited by 43 · see citing works
Self-citationShen, J., & Zhu, Z. (2008) · PubMed · Cited by 42 · see citing works
Alderson, R. F., Toki, B. E., Roberge, M., et al. (2006) · Bioconjugate Chemistry · doi:10.1021/bc0503521 · Cited by 40 · see citing works
Morecki, S., Lindhofer, H., Yacovlev, E., Gelfand, Y., Ruf, P., & Slavin, S. (2008) · Experimental Hematology · doi:10.1016/j.exphem.2008.03.005 · Cited by 38 · see citing works
Intrabody-Based Approaches to Cancer Therapy: Status and Prospects
Williams, B. R., & Zhu, Z. (2006) · Current Medicinal Chemistry · doi:10.2174/092986706776872899 · Cited by 37 · see citing works
Borrebaeck, C. A. K. (2001) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(01)00070-4 · Cited by 33 · see citing works
Intrabody strategies for the treatment of human papillomavirus-associated disease
Doorbar, J., & Griffin, H. M. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.5.677 · Cited by 33 · see citing works
Visintin, M., Melchionna, T., Cannistraci, I., & Cattaneo, A. (2008) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2008.02.012 · Cited by 32 · see citing works
Protein i: interference at protein level by intrabodies
Manikandan, J. (2006) · Frontiers in bioscience · doi:10.2741/2152 · Cited by 15 · see citing works
Protein transduction technology
Matsushita, M., & Matsui, H. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0633-1 · Cited by 13 · see citing works
Intracellular antibodies: a revolution waiting to happen?
Stocks, M. (2006) · PubMed · Cited by 7 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The evolution of commercial drug delivery technologies
Vargason, A. M., Anselmo, A. C., & Mitragotri, S. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00698-w · Cited by 1,361 · see citing works
Therapies for rare diseases: therapeutic modalities, progress and challenges ahead
Tambuyzer, E., Vandendriessche, B., Austin, C. P., Brooks, P. J., Larsson, K., Miller Needleman, K. I., Valentine, J., Davies, K., Groft, S. C., Preti, R., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0049-9 · Cited by 357 · see citing works
Bispecific antibodies for cancer therapy: The light at the end of the tunnel?
Chames, P., & Baty, D. (2009) · mAbs · doi:10.4161/mabs.1.6.10015 · Cited by 336 · see citing works
Self-citationMERS-CoV spike protein: a key target for antivirals
Du, L., Yang, Y., Zhou, Y., Lu, L., Li, F., & Jiang, S. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1271415 · Cited by 301 · see citing works
How mRNA therapeutics are entering the monoclonal antibody field
Van Hoecke, L., & Roose, K. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1804-8 · Cited by 205 · see citing works
mRNA mediates passive vaccination against infectious agents, toxins, and tumors
Thran, M., Mukherjee, J., Pönisch, M., Fiedler, K., Thess, A., Mui, B. L., Hope, M. J., Tam, Y. K., Horscroft, N., Heidenreich, R., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201707678 · Cited by 166 · see citing works
Regulation of efferocytosis as a novel cancer therapy
Zhou, Y., Yao, Y., Deng, Y., & Shao, A. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00542-9 · Cited by 100 · see citing works
Modulation of Signaling Mediated by TSLP and IL-7 in Inflammation, Autoimmune Diseases, and Cancer
Marković, I., & Savvides, S. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01557 · Cited by 86 · see citing works
Jin, Y., Lin, Z., Xu, Q., Fu, C., Zhang, Z., Zhang, Q., Pritts, W. A., & Ge, Y. (2019) · mAbs · doi:10.1080/19420862.2018.1525253 · Cited by 68 · see citing works
The dark side of Tregs during aging
Palatella, M., Guillaume, S. M., Linterman, M. A., & Huehn, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.940705 · Cited by 58 · see citing works
Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy
Smith, J. B., Lanitis, E., Dangaj, D., Buza, E., Poussin, M., Stashwick, C., Scholler, N., & Powell, D. J. (2016) · Molecular Therapy · doi:10.1038/mt.2016.149 · Cited by 58 · see citing works
Sphinx: merging knowledge-based and<i>ab initio</i>approaches to improve protein loop prediction
Marks, C., Nowak, J., Klostermann, S., Georges, G., Dunbar, J., Shi, J., Kelm, S., & Deane, C. M. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btw823 · Cited by 56 · see citing works
Engineering humoral immunity as prophylaxis or therapy
Deal, C. E., & Balazs, A. B. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.06.014 · Cited by 27 · see citing works
Rezaie, F., Davami, F., Mansouri, K., Agha Amiri, S., Fazel, R., Mahdian, R., Davoudi, N., Enayati, S., Azizi, M., & Khalaj, V. (2017) · Journal of Applied Microbiology · doi:10.1111/jam.13483 · Cited by 15 · see citing works
- Authors
- Chames, P., Van Regenmortel, M., Weiss, E., & Baty, D.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Chames, Patrick
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2009-04-28
- Volume
- 157
- Issue
- 2
- Pages
- 220-233
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- PMC
- PMC2697811
- OpenAlex
- W1580407891
- Cited by
- 1,382
- References
- 86
- Citations by year
- 2026: 52 · 2025: 98 · 2024: 90 · 2023: 104 · 2022: 90 · 2021: 125 · 2020: 142 · 2019: 110 · 2018: 111 · 2017: 99 · 2016: 97 · 2015: 88 · 2014: 62 · 2013: 45 · 2012: 20
- FWCI
- 3.39
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- British Journal of Pharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Keywords
- therapeutic antibodies, monoclonal antibodies, Fc receptor polymorphism, pharmacokinetics, immune interactions, antibody engineering, drug delivery, autoimmune disease, cancer therapy, inflammation
- MeSH terms
- Animals, Antibodies, Monoclonal, Genetic Vectors, Humans, Models, Molecular, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
